Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus

Endocr J. 2022 Nov 28;69(11):1281-1284. doi: 10.1507/endocrj.EJ20220831. Epub 2022 Oct 14.

Abstract

"What's in a name? That which we call a rose/By any other name would smell as sweet." (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and pediatric endocrine societies now proposes changing the name of "diabetes insipidus" to "Arginine Vasopressin Deficiency (AVP-D)" for central etiologies, and "Arginine Vasopressin Resistance (AVP-R)" for nephrogenic etiologies. This editorial provides both the historical context and the rational for this proposed name change.

Keywords: Diabetes insipidus; Renaming.

MeSH terms

  • Arginine Vasopressin* / deficiency
  • Diabetes Insipidus* / classification
  • Diabetes Mellitus
  • Humans
  • Societies, Medical

Substances

  • Arginine Vasopressin